Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Complement Factor I (CFI) profile biomarker-positive result~* Women of child bearing potential and men should remain abstinent or use contraceptive methods~Exclusion Criteria:~* History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in study eye~* Previous subfoveal focal laser photocoagulation in study eye~* Laser photocoagulation in the study eye~* Prior treatment with external-beam radiation therapy or transpupillary thermotherapy in study eye~* Previous intravitreal drug administration in study eye. A single intraoperative administration of a corticosteroid during cataract surgery at least 3 months prior to screening is permitted~* Previous cell-based intraocular treatment in study eye~* Intraocular surgery in study eye~* Uncontrolled glaucoma and history of glaucoma-filtering surgery in study eye~* History of corneal transplant in study eye~* GA in either eye due to causes other than AMD~* Proliferative diabetic retinopathy in either eye~* Active or history of neovascular (wet) AMD in either eye~* History of idiopathic or autoimmune-associated uveitis, ocular or intraocular conditions, and infectious or inflammatory ocular disease~* Active uveitis and infectious conjunctivitis, keratitis, scleritis or endophthalmitis~* Previous systemic treatment with complement inhibitor and with inhibitors/modulators of visual cycle~* Previous expression vector mediated intraocular treatments~* Uncontrolled blood pressure and atrial fibrillation~* Medical conditions associated with clinically significant risk for bleeding-~* Predisposition or history of increased risk for infection~* Active malignancy within the previous 12 months except for appropriately treated carcinoma in situ of cervix, resolved non-melanoma skin carcinoma, and prostate cancer with a Gleason score of less than or equal to 6, and a stable prostate-specific antigen for greater than or equal to (\>/=) 12 months~* History of severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of lampalizumab injection~* Women of child bearing potential must have a negative serum pregnancy test within 28 days prior to initiation of study treatment~* Previous participation in other studies of investigational drugs

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lampalizumab: Open-label Safety Run-In (Type: EXPERIMENTAL): Participants will receive 10 milligrams (mg) lampalizumab intravitreally Q2W during the safety run-in period.
- Q2W Lampalizumab: Randomized Treatment (Type: EXPERIMENTAL): Participants will receive 10 mg dose of lampalizumab intravitreally Q2W during the 24-week treatment period.
- Q4W Lampalizumab: Randomized Treatment (Type: EXPERIMENTAL): Participants will receive 10 mg dose of lampalizumab intravitreally Q4W during the 24-week treatment period.
- Sham: Randomized Treatment (Type: SHAM_COMPARATOR): Participants randomized to control arms will receive sham injections, that mimics intravitreal injection of lampalizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).